Contract Pharma Manufacturing News

  1. Results Of Nanoform Collaborative Study To Be Presented At U.S. Drug Delivery & Formulation (DDF) Summit 9/11/2025

    Nanoform, a leading nanoparticle medicine performance-enhancing company, announced that key findings from two studies conducted in collaboration between Nanoform and Takeda will be presented at the 15th American Drug Delivery & Formulation Summit (DDF) in Boston, Mass., on September 16, 2025, at 09:10 – 09:40 in Room 1.

  2. Cellectar Biosciences And ITM Enter Supply Agreement For GMP-Grade Actinium-225 9/11/2025

    Cellectar Biosciences, Inc. (Nasdaq: CLRB, “Cellectar”), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, and ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced a supply agreement for Actinium-225 (Ac-225). The agreement will support the clinical development of Cellectar’s actinium-labeled phospholipid ether (PLE) radiopharmaceutical candidates, including its Phase 1-ready compound, CLR 121225, for the treatment of solid tumors.

  3. Cytiva And WhiteLab Genomics Team Up To Use AI To Accelerate Cell Line Development 9/10/2025

    Cytiva, a Danaher company and a global leader in the life sciences industry, and WhiteLab Genomics, a techbio company specializing in artificial intelligence for genomic medicine research and development, announced a collaboration to accelerate the development of next-generation genomic medicines.

  4. Symeres Acquires DGr Pharma To Enhance Regulatory Expertise And Broaden Its Biopharma Capabilities 9/10/2025

    Symeres, a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announces the acquisition of DGr Pharma, a drug development-focused consultancy, to expand its integrated early-stage drug development services and accelerate IND-enabling capabilities for biopharma clients.

  5. NKGen Biotech, Inc. Announces Completion Of NKMax Co., Ltd. Acquisition; Gains Full Control Of Global Manufacturing And Intellectual Property Assets 9/9/2025

    NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced the successful completion of its acquisition of a majority equity stake in NKMax Co., Ltd. (“NKMax”), a Korean biotechnology company, out of bankruptcy.

  6. GBI Biomanufacturing Partners With NanoRetinal To Advance Vision-Restoring Therapy For Inherited Retinal Diseases 9/9/2025

    GBI Biomanufacturing (GBI), a leading US-based contract development and manufacturing organization (CDMO), is pleased to announce a partnership with NanoRetinal, Inc. to develop and manufacture NAR-001, NanoRetinal's proprietary nanoparticle technology designed to restore and/or preserve vision in patients with Inherited Retinal Diseases (IRD).

  7. Kytopen Announces Collaboration With BlueWhale Bio To Revolutionize Cell Therapy Manufacturing 9/9/2025

    Kytopen Corp., a leader in providing continuous flow cellular engineering technologies, announced today its collaboration with BlueWhale Bio, Inc., a company dedicated to accelerating the growth and adoption of cell-based therapies by transforming the manufacturing process of immune cell therapies.

  8. Wheeler Bio And Pharmefex Consulting Announce Strategic Partnership To Integrate IND Drafting And CMC Support Into Wheeler's ModularCMC™ Platform 9/9/2025

    Wheeler Bio, Inc., a U.S.-based contract development and biomanufacturing organization (CDMO), today announced it has established a strategic partnership with Pharmefex Consulting, an expert CMC consultancy with deep expertise in regulatory strategy and technical operations, focused on accelerating client success in Investigational New Drug (IND) filings and regulatory submissions.

  9. Kenox Enters Into Strategic Product Development Partnership With Strides 9/9/2025

    Strides Pharma Science Ltd today announced that its step-down, wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has entered into a strategic product development partnership with Kenox Pharmaceuticals Inc. ("Kenox"), a fast-growing contract development and manufacturing company specializing in Orally Inhaled and Nasal Drug Products (OINDPs).

  10. Almac Group Expands Bioavailability Enhancement Capabilities – Addressing A Critical Need In Drug Development 9/9/2025

    Almac Group has completed a multi-million-pound expansion of its bioavailability enhancement capabilities at its facility in Charnwood, UK.